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awareness of this industry is poor (Safran 
et al., 2007; Bailey, 2006). Selling health 
data to stakeholders with a commercial 
interest raises a number of ethical issues 
and concerns.
The commercialisation of public 
health data and the potential for 
generating supplementary health revenue 
has been explored by a number of 
countries, with many now engaged in 
commercial relationships with a range of 
entities, including research organisations 
(public and private) engaged in research 
variously in pharmacovigilance, disease 
epidemiology, pharmaco-economic 
studies, and health service provision 
and delivery; insurance companies; and 
pharmaceutical companies. In New 
Zealand the common argument for the 
commercialisation of public health data 
tends to rest on the following assertions: 
health data in New Zealand is considered 
‘public’ because the health sector is 
primarily funded through central 
government budget allocations; the public 
health system is for the public good; the 
public health system is increasingly under 
financial pressure to provide services 
and care to an ageing population; there 
In May 2013 Kathryn Ryan of Radio New 
Zealand interviewed Hayden Wilson, 
a partner at law firm Kensington Swan 
specialising in health privacy and public 
service issues, and Graeme Osborne, 
director of the National Health Informa-
tion Technology Board, about a range of 
issues connected to health databases and 
the sharing of health data in New Zealand. 
Wilson noted that commercialisation of 
large-scale health data ‘is a very difficult 
policy question’. Osborne commented: 
‘I have noticed recently that insurance 
companies have been approaching GPs for 
patient information … [this] must be up 
to the individual and they must consent’ 
(Radio New Zealand, 2013).
The use of health data is widespread 
in both the public and private sectors 
globally (Gauld, 2004; Martin et al., 
2014). The sale of health data and health-
related data is now a multi-million 
dollar industry, involving both private 
and public organisations, and yet public 
Page 78 – Policy Quarterly – Volume 11, Issue 4 – November 2015
is a need to identify potential sources of 
revenue; commercialising health data sets 
provides a potential source of revenue 
and so in this context is in the interests 
of the public good and public health 
(Gauld 2004; Bodenheimer 2008; Nolte 
and McKee, 2008).
Objections to the commercialisation 
of public health data commonly hinge 
on the implications for individuals 
with respect to rights and privacy 
and the right to informed consent. In 
countries where health data has been 
commercialised, attention has been paid 
to the development of protocols and 
frameworks which address the risks to 
privacy and information security and of 
impingement on the rights of individuals 
(Brezis, 2008). It is assumed that once 
these have been addressed the sale of 
health data can proceed, as it is in the 
public good. The approach has tended 
to be to address the privacy and consent 
issues at the level of the individual and 
then proceed with commercialisation, 
thus assuming that ‘ethical’ issues have 
been sufficiently dealt with and that 
there are no further issues with respect 
to the public good. As we will see, this is 
problematic.
Generally, the two main ethical 
frameworks operating here are a utilitarian 
framework and a rights-based framework 
(Smith and Duffy, 2003; Lovelock and 
Lovelock, 2013; Taylor, 1975). Both of 
these frameworks have limitations. Briefly, 
in the utilitarian view, actions are good 
when they increase the overall pleasure 
(well-being) of the group and when they 
decrease pain for the community. An 
act is considered superior if it produces 
greater overall well-being. Under this 
model, acts can be evaluated in terms 
of their own consequences, rather than 
being seen to be predetermined by social 
norms and rules. Thus, commercialisation 
may go against social norms and rules, 
but if it produces greater overall well-
being (generates revenue for the public 
health system and/or improved health 
outcomes) it is considered moral and 
ethical. The problem with this is that 
greater overall well-being or the happiness 
of the majority does not always address 
the well-being of the minority, and, in 
health, such an approach could lead to 
increased marginality of minorities and 
poorer health outcomes amongst those 
who are already disadvantaged (Lovelock 
and Lovelock, 2013). This is discussed 
below in relation to pharmaceutical and 
insurance companies.
Rights frameworks also have 
limitations, as rights are socially and 
politically created. We need then to ask: 
what understanding of rights is being 
embraced? Is this understanding culturally 
specific or universal? Universalistic 
approaches to rights, which are evident 
in this field, have been critiqued as a 
manifestation of a move towards global 
governance, underpinned by a desire 
of developed nations to consolidate 
their wealth and power (Chandler, 
2002, 2003). Important in terms of the 
commercialisation of health data is the 
question of whether rights issues (patient 
rights to informed consent, to control 
over data, to confidentiality) are being 
addressed in practice, not just rhetoric. To 
date there has been no evaluative research 
which has examined whether the various 
protocols and frameworks adopted 
internationally are serving the interests of 
patients, or whether commercialisation of 
health data is undermining the interests 
or rights of patients (or the public). The 
argument here is not that the concept 
of rights is valueless; rather it is the 
absence of a critical appraisal of what is 
happening in practice. There is evidence 
to suggest that rights are seldom applied 
equally in societies that are fundamentally 
unequal, and even less likely to be applied 
equally across societies where there are 
vast differences in prosperity (Chandler, 
2002). We need to explore the impact 
of the commercialisation of health data 
on rights, how rights are addressed, and 
whose rights are likely to be compromised, 
at home and abroad.
Finally, and again briefly, this area 
would benefit from the employment of 
the principles of social justice. Rawls’ 
(1971) notion of justice as ‘fairness’ 
is one of many conceptions that can 
be usefully employed to examine the 
commercialisation of health data. Central 
to Rawls’ conception is the notion that 
fairness is paramount, and here – in 
contrast to the utilitarian approach – 
decisions do not rest on what is best for 
the majority, but on what is right for the 
individual and the social group. Here, 
just decisions are so defined not by a 
person’s social position and self-interest, 
but in terms of what is fair for those who 
are disadvantaged or less well-off (Pogge, 
2005). While it can be argued that issues 
relating to the sale of health data are 
pertinent to everyone, the impact of 
this practice is not necessarily shared 
equally. Hence, the concept of ‘fairness’ 
allows consideration of unequal impact 
on individuals and certain social groups. 
This is discussed more fully below in 
relation to the pharmaceutical industry 
and ethnic minority groups. Further, 
distributive or redistributive justice is 
within this framework considered a 
moral duty. Thus, if commercialisation 
was demonstrated to be unfair to some, 
this ethic would require action against 
commercialisation. 
Finally, fundamental to any ethical 
decision-making is a commitment to 
critically appraise the issue or problem, 
identify where values conflict, and seek 
resolution to the questions they provoke 
via a range of ethical frameworks.
The use of health data sets by research 
organisations
There is evidence of the use of linked data 
sets for research purposes. For example, in 
the United Kingdom the General Practice 
Research Database, developed in 1993, was 
The NHS data sets include information 
on prescribed primary care drugs; 
administered hospital drugs; laboratory 
data; consultations; general practitioner 
[etc].
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merged with the Clinical Practice Research 
Datalink in 2011. This was a jointly-
funded initiative of the National Institute 
for Health Research and the Medicines 
and Healthcare Products Regulatory 
Agency, overseen by the National Health 
Service (NHS) (Department of Health, 
2011). Its purpose is to support research 
capability and it is linked directly to policy 
on increasing research and innovation 
in health and social care. The provision 
of these new data and research services 
is promoted in terms of what they can 
offer for new treatment options and 
insights into serious health conditions. 
The NHS data sets include information 
on prescribed primary care drugs; 
administered hospital drugs; laboratory 
data; consultations; general practitioner 
and hospital-coded disease data; disease 
registers, and cancer registers. Data can be 
bought for a fraction of what it would cost 
to conduct the primary research. The data 
sets provide data on 64 million patients, 
and partnerships with other European 
countries are currently being developed. 
The key ethical concerns in relation 
to this use of the NHS data sets have 
focused on who has access to the database, 
and the importance of maintaining 
confidentiality. These issues are addressed 
through a scientific and ethical advisory 
group, which is responsible for granting 
access approval and addresses issues 
surrounding the scientific validity of the 
proposed studies and the need to ensure 
anonymisation. Revenue generated by 
sales of data to researchers and research 
organisations funds the database.
In the United States similar issues have 
been addressed with respect to access 
to health data by researchers. There, as 
in the UK, advocates of patient privacy 
stress the potential misuse and unethical 
disclosure of sensitive health data and the 
implications for individuals. Connected 
to this is the argument that misuse of 
sensitive health data may or can harm 
already marginalised or stigmatised 
individuals (Hodge, 2003). Conversely, 
others stress the importance of identifiable 
health data for public health practice, 
including monitoring and establishing 
patterns of injury and disease for 
populations, facilitating surveillance, and 
furthering epidemiological investigation 
and the identification of health needs. The 
regulatory measures in this area attempt to 
balance individual privacy rights and the 
public interest in public health outcomes 
(ibid.). In the US, the Department of 
Health and Human Services Privacy Rule 
(discussed below) addresses this tension. 
Ultimately, protecting individual privacy 
protects public health objectives: it is 
argued that eroding the former leads to 
a loss of trust, falling participation in 
public health programmes, and thus 
poorer data for epidemiological research 
and informed interventions. However, 
protecting privacy is not always a case 
of closing off access. There are legitimate 
uses that do impinge on privacy, and this 
is usually in the event of a public health 
crisis. Privacy and public health have a 
synergistic relationship and, necessarily, 
privacy regulations are complicated.
In Australia, privacy and confidentiality 
are the central issues discussed in the 
literature, with the focus being primarily 
on the use of health data for research. For 
example, Kelman and Holman (2002) 
discuss the linkage protocol used for a 
study on diabetes in Western Australia. 
The best-practice protocol employed 
by this research team was designed to 
provide maximum protection of private 
and confidential information. It involved 
separating personal identifiers from actual 
health data and confining the use of 
personal identifiers to the initial linkage 
stage. Four broad principles underpin 
this protocol for inter-agency record 
linkage: (1) maximise the protection of 
individual privacy; (2) provide linked 
data files only to nominated researchers 
involved in specific, approved research 
projects; (3) provide researchers with 
no more than the data sets required for 
their specific project; and (4) assure data 
custodians that the data that is their 
responsibility will be used appropriately 
and that security obligations will be met.
Research and commercial use in the United 
States
In 2003 the United States introduced the 
Privacy Rule, which established a national 
standard for health information privacy 
and security (Hodge, 2003). The Privacy 
Rule stands alongside a range of other 
regulatory measures at both national and 
federal levels. Individually-identifiable 
health data had always been shared with 
a range of both public and private sector 
agencies (such as pharmacies, insurance 
companies) in the United States, and 
this sharing has also taken place without 
individual consent. US law addressing the 
sharing of health data is fragmented. The 
constitution does not grant protection 
of privacy of health data to individuals. 
Federal and state-level regulations domi-
nate. These include, at the federal level, 
the Freedom of Information Act 1966, the 
Privacy Act 1974 and the E-Government 
Act (2002), and a range of federal-level 
privacy laws relating to research subjects 
and protecting confidentiality both for 
institutions and individuals. There are 
a range of statutory laws at the state 
level which tend to regulate specific data 
recipients (e.g. insurers), specific medical 
tests (e.g. genetic) and particular data 
sources (e.g. health care facilities); there 
are also public health laws, regulations 
for insurers and licensing statutes which 
address privacy protections. But the key 
measure is the Privacy Rule.
The Privacy Rule covers a range of 
entities – health care providers, insurers 
and government health programmes – 
Individually-identifiable health data had 
always been shared with a range of both 
public and private sector agencies ... 
in the United States, and this sharing 
has also taken place without individual 
consent.
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that conduct transactions electronically. 
There are, however, other organisations 
which use, disclose or store public health 
information that are not directly covered. 
The rule protects most individually-
identifiable health information (PHI), 
electronic or paper-based, kept by the 
entities covered. Public health data that 
has been de-identified is not included 
(this data must have been stripped of 
unique identifiers). Those entities to 
which the rule applies must: 
•	 provide	notification	to	individuals	
regarding their privacy rights and 
how their PHI is used or disclosed;
•	 adopt	and	implement	internal	
privacy policies and procedures;
•	 train	employees	to	understand	
privacy policies and procedures;
•	 designate	person(s)	to	be	responsible	
for the implementation of privacy 
policies and procedures;
•	 establish	appropriate	administrative,	
technical and physical safeguards to 
protect the privacy of PHI;
•	 meet	their	obligation	to	health	
consumers who exercise their rights 
under the Privacy Rule to inspect and 
request corrections or amendments 
to their PHI.
There is a range of circumstances 
under which the information can be 
disclosed. Generally, disclosure cannot 
take place without written consent 
from the individual. However, there are 
exceptions. These are when the individual 
requests a copy of their PHI, and when 
the Department of Health and Human 
Services requires access to PHI to facilitate 
a compliance investigation under the rule. 
There are also certain disclosures that do 
not require individual consent:
•	 providing	a	PHI	to	law	enforcement	
agencies;
•	 for	judicial	and	administrative	
proceedings;
•	 for	commercial	marketing;
•	 to	parents	of	un-emancipated	
minors;
•	 to	family	members,	friends,	
significant others or caregivers, in 
cases of emergency or during care-
taking functions;
•	 for	health	research,	if	a	waiver	has	
been provided by an institutional 
review board (ethics review 
committee);
•	 to	public	health	authorities	for	public	
health purposes.
More generally, the Privacy Rule 
pre-empts many state-level or local laws 
– ‘The Rule serves as a federal floor of 
protections’ – but it does not pre-empt 
state or local laws that contain greater 
specificities or stringencies. Thus, all laws 
that are more stringent and protective of 
health information privacy rights remain 
in effect (Hodge, 2003, p.668).
With respect to public health practice, 
the rule, through exemption clauses, 
allows a balance between individual 
privacy and public health considerations. 
There is, however, always the possibility 
that the rule will be poorly applied – for 
example, through misinterpretation of 
who can have access to PHI – and barriers 
emerge for public health practice. There 
is also a reported misperception about 
how the data can be used (Hodge, 2003), 
where it is perceived that the rule leads to 
restrictions on use.
Pharmaceutical and insurance companies
While there are ethical issues connected 
to the use of health data by research 
organisations, as identified above, major 
ethical flags are raised with respect to 
insurance and pharmaceutical companies. 
With respect to pharmaceutical companies, 
there are issues connected to the use 
of data for research and development 
purposes which may well be addressed 
through various research ethics bodies 
or committees at an industry, university 
or national level. We should, however, be 
cautious about separating out market and 
profit imperatives from research agendas 
in this industry, as often the two are closely 
entwined (Avorn, 2005). In addition, the 
use of data to identify profitable gaps in 
the market carries with it a number of 
ethical issues and concerns, in particular 
the potential and likelihood of targeting 
vulnerable populations (for example, the 
aged and those with chronic conditions), 
and where at least one component of 
multiple vulnerabilities can be health 
literacy. Direct-to-consumer advertising 
presents a range of ethical concerns, 
from challenges to individual rights to 
the potential for overuse of marginally 
effective technologies, and thus potentially 
poor public health care, again more 
likely to be taken up by the vulnerable 
(Moynihan and Cassels, 2005). Further, it 
is possible that the revenue generated for 
the public health system by data sales to 
pharmaceutical companies is undermined 
by the conflict of interest between the 
profit motive underpinning this industry 
and the interests and objectives of public 
health (Brezis, 2008). The literature also 
reveals that voluntary ethical guidelines 
often fail (Chalmers, 2006).
With respect to insurance companies, 
data use can also be applied to product 
development and targeting sales, and it is 
not clear what ethical processes would be 
put in place to ensure that this targeting 
did not perpetuate existing inequalities 
(that is, disparities in health outcomes 
between different societal groups) or 
create new inequalities in coverage 
requirements or entitlements. A great 
deal of emphasis is placed on privacy 
and its protection through the de-
identification of data, but it is also known 
that it is possible to re-identify data after 
it has been de-identified. Thus, there are 
ethical issues connected to the potential 
for insurance companies (or any other 
commercial entity, for that matter) to 
re-identify de-identified data (MacRae, 
Dobbie and Ranchhod, 2012) in order 
... the use of data to identify profitable 
gaps in the market carries with it a 
number of ethical issues and concerns, 
in particular the potential and likelihood 
of targeting vulnerable populations ...
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to target more effectively and maximise 
commercial gain.
Public debate, understanding and 
transparency
In April 2006 the American Medical 
Informatics Association convened a 
panel of stakeholders to discuss the 
issues connected with the secondary 
use of health data (Safran et al., 2007). 
The stakeholders identified key findings 
and made a range of recommendations 
detailed in Table 1 (amended slightly). 
All of these recommendations and the 
discussion that surrounded them are of 
potential utility in New Zealand.
New Zealand
Health data in de-identified form is 
routinely used in New Zealand for 
research purposes. Under the New 
Zealand Health Information Privacy 
Code data is provided on the basis that 
the individual will not be identified in 
any published form. To de-identify data, 
commonly the NHI number is removed, 
as is the name and address information 
(MacRae, Dobbie and Ranchhod, 2012). 
As noted above, there are a range of 
international protocols which address 
patient privacy within health information. 
Privacy is highlighted as a key issue and a 
potential barrier to the commercial use 
of health data, and it is typically argued 
that this key ethical issue can be addressed 
through de-identification. However, more 
recently concern has been raised about 
the risk of re-identification of health data 
(ibid.). The current recommendation is 
that de-identified data sets should contain 
more than 150,000 individuals, not be 
accompanied by meshblock data, and have 
age and ethnicity data aggregated. Further, 
agreements must be in place with ‘trusted’ 
organisations, as de-identified data can be 
re-identified readily (ibid.).
Ethics and privacy policy framework
There are a number of questions that 
need to be addressed in the New Zealand 
context if an ethical pathway is to be 
identified for the secondary use of health 
data and the commercialisation of public 
health data sets. Answers to some of these 
questions are suggested in the small body 
of research canvassed above, but there are 
some more preliminary steps which need 
to be taken before any ethics and privacy 
policy framework can be developed in 
New Zealand.
First, there are fundamental questions 
that need to be addressed by stakeholders, 
including (but not exhaustively):
•	 What	are	the	potential	benefits	and	
risks of the secondary use of health 
data?
•	 Who	owns	health	data,	and	who	has	
the right to access the data and for 
what purposes?
•	 What	obligations	might	exist	in	
relation to the Treaty of Waitangi?
•	 What	are	the	public	trust	issues	
with respect to patient consent for 
secondary use of health data?
•	 Do	patients	have	the	right	to	audit	
or put limits on access to their health 
data, even after anonymisation?
•	 How	can	we	reconcile	public	good	
with the rights of individuals?
•	 Innovative	technologies	may	enhance	
the ability and ease of widespread 
data-sharing and additional 
commercial uses: what problems may 
arise from this?
•	 What	can	be	done	about	
inappropriate use or exploitation of 
data-sharing?
What can be done if de-identified data is 
re-identified?
•	 What	regulations,	legislation	and/or	
policies and procedures are needed to 
address these issues? (adapted from 
Safran et al., 2007).
In addition, there are a number of 
subsequent questions related to selling, 
payment and ownership of health data 
from the public health system. This is 
particularly an issue when a data-holding 
entity is an independent business that 
receives public funding subsidy (for 
Table 1: Recommendations of potential utility for New Zealand
Recommendation Discussion
Increase transparency 
of data use and 
promote public 
awareness.
Ongoing public policy discussions must explicitly and directly 
address the secondary use of health data. Conducting and managing 
these activities must enlist diverse stakeholders and fully disclose 
uses and safeguards through open and readily accessible processes.
Focus ongoing 
discussions on 
data access, use 
and control, not on 
ownership.
Consensus-building meetings encompassing a broad constituency 
must focus on data access and control policies and practices for 
secondary use of data. Focus should emphasise access and control, 
not ownership. Discussants should consider best approaches to risk 
management and mitigation.
Discuss privacy 
policies and security 
for secondary use of 
health data.
To develop consensus on pivotal issues, public and private sector 
organisations advancing the use of health information should 
promote discussions that include a range of stakeholders. Ongoing 
discussions must address complex issues related to private and 
secure secondary use of health data.
Increase public 
awareness of benefits 
and challenges 
associated with 
secondary use of 
health data.
A wide range of interested parties, especially consumer-orientated 
patient and caregiver groups, should promote public education 
regarding benefits of secondary use of health data. A first step is 
to identify appropriate organisations and agencies that have a role 
to play in this effort. The aim of the education is to build public 
awareness and trust in secondary use of health data.
Create a taxonomy 
for secondary uses of 
health data.
A taxonomy identifying possible non-clinical uses of personal 
health information is needed to clarify societal, public policy, legal 
and technical issues. The taxonomy will support more focused, 
productive discussions regarding health data and its use.
Address, 
comprehensively, 
the difficult, evolving 
questions related 
to secondary use of 
health data.
Questions to address encompass data transparency; consumer 
awareness and understanding; technical issues and challenges of 
identity management and user authentication; commercialisation 
and sale of data; and oversight. The de-identification and 
anonymisation of data merit additional attention by technical experts 
in authentication, de-duplication and identity management.
Focus national and 
state attention on 
the secondary use of 
health data.
Findings of panels should be shared with all interested stakeholders. 
Additional efforts should be undertaken to formulate a road map 
which depicts the multi-tiered use and re-use of health data; the 
road map should take into account all foreseeable applications and 
the full complexity of issues.
Source: adapted from Safran et al., 2007
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example, general practices). How much 
should providers be paid for the use of 
their data? And what does the payment 
represent? Is payment for raw material 
or is it for the underlying investment 
to capture data? (This is particularly an 
issue where providers fund their own 
information systems. It is, however, a 
complex issue, because in most instances 
providers are publicly funded to capture 
that data for other purposes – for 
example, the Integrated Performance 
Incentive Framework.)
Some suggestions
We believe a number of issues surrounding 
the commercialisation of health data 
in New Zealand require addressing and 
suggest the following as a start.
1. To provide and focus public debate 
on this issue we suggest that the 
issue of the commercialisation of 
New Zealand health data be referred 
to the parliamentary Health Select 
Committee. 
2. Based on the deliberations and findings 
of the Health Select Committee, a 
policy should  be developed on the 
secondary use of health data which 
adequately addresses ethically its 
commercialisation.
3. This policy should address issues 
of privacy at the level of the patient 
(suggestions overseas include opt-in 
and opt-out clauses where patients 
‘consent’ or not to the use of their 
individual data). There is a need, 
however, to recognise that there may 
be differences in cultural response to 
this: consent, for example, may not be 
an issue at the level of the individual 
patient but may be required from 
a wider, related social group (e.g. 
whänau or iwi). Thus, in such a 
case consent may not be given by 
the individual because it is required 
from their group. In addition, there 
is a need to acknowledge that value 
is a contested concept, particularly 
among indigenous populations. In 
New Zealand it seems reasonable 
to assume that the sale of health 
data will be contested by Mäori in 
terms both of ownership and of the 
assumed right to sell health data to 
commercial enterprises abroad. It also 
seems reasonable to assume that other 
members of New Zealand society will 
contest commercialisation of this 
data. 
4. Any policy development needs 
to accept that there is no unified 
consumer position, which means 
that patient consent is going to be a 
complex process.
5. While in the United States it has been 
argued that a focus on ownership 
detracts from the development of 
policy, in New Zealand it seems likely 
that the issue of ownership will be 
important, not only with respect to 
the ‘right to sell’, but also in terms of 
conflicting understandings of what 
the ‘value’ of health data is. It can be 
argued that we have reached a point 
currently in New Zealand where 
ownership is not contested, as both the 
patient and provider are the stewards 
of health data, with both having 
rights to ownership such that they 
cannot diminish each other’s right, 
but there remains the question of 
whether commercialisation of health 
data references the sale of something 
else; that is, commercialisation may 
challenge current conceptions of 
ownership. 
6. It would be necessary to engage 
a wide range of stakeholders to 
ensure mitigation of future risks of 
commercialisation. These stakeholders 
would include, for example, those who 
Table 2: Current legislation of relevance
The following legislation has relevance for the commercialisation of New Zealand health 
data. The development of an ethics and privacy policy framework would have to work within 
these legislative parameters.
The Public Records Act 2005 provides a comprehensive framework for the systematic 
creation and preservation of public archives and local authority archives. This act gives the 
chief archivist, who is also the chief executive of Archives New Zealand, powers of direction 
with respect to archiving and disposal decisions concerning health information held by the 
public sector.
The New Zealand Public Health and Disability Act 2000, section 3(1)(d) describes one 
of the act’s objectives as: to facilitate access to, and the dissemination of information to 
deliver, appropriate, effective and timely services.
The Health (Retention of Health Information) Regulations 1996 set a minimum period of 
ten years for which health information must be held by health or disability service providers. 
They also address the form in which health information is to be retained and the obligations 
associated with the transferring of health information. 
The Health Information Privacy Code 1994 is a code of practice issued by the privacy 
commissioner under section 46 of the Privacy Act which gives extra protection to health 
information because of its sensitivity. It covers all health agencies, and protects all personal 
health information relating to an identifiable individual. The Ministry of Health has a 
responsibility to ensure it complies with this code in respect to all health information 
entrusted to it.
The Privacy Act 1993 provides a general framework for promoting and protecting individual 
privacy. It establishes certain principles with respect to the collection, use, disclosure of and 
access to information relating to individuals. It applies to private and public sector agencies. 
The role of the privacy commissioner is to investigate complaints about interferences with 
individual privacy.
The Cancer Registry Act 1993, section 4 and the Cancer Registry Regulations 1994 
require the director-general of health to maintain or arrange for the maintenance of a cancer 
registry.
The Official Information Act 1982 was established to make official information freely 
available. This has relevance when a request for health information to the Ministry of Health 
is from someone who is not the subject of the information or their personal representative, 
as addressed in part II of the act.
The Health Act 1956 gives the Ministry of Health the function of improving, promoting 
and protecting public health. It contains specific provisions in section 22 governing the 
disclosure of health information about identifiable individuals by and between health service 
providers and other agencies with statutory functions. 
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collect the data for primary use; those 
who use the data for non-clinical 
use; patients and the public; policy 
developers; those who inform and 
educate health professionals, industry, 
patients and the public; and non-
governmental organisations which 
address health-related issues. 
7. It would also be useful to conduct a 
thorough assessment of the risk of re-
identification of de-identified health 
data.
In addition, several steps need to be 
taken for the commercialisation of New 
Zealand health data to be addressed 
ethically. These include:
•	 raising	public	awareness	of	the	
possibility of the commercialisation 
of New Zealand health data;
•	 transparency	in	the	uses	of	health	
data;
•	 adequate	public	education,	
discussion, and debate between and 
across stakeholder groups;
•	 understanding	that	there	are	multiple	
meanings around ‘value’;
•	 adequate	debate	on	and	resolution	
of the tension between community 
‘good’ and individual rights, and 
acknowledgement that recognition 
of individual rights does not always 
undermine community good;
•	 recognition	that	utilitarian	ethics	
emphasises greater overall well-being 
(or social good), but when applied 
can also, while addressing the good 
of the majority, overlook good for 
minorities and perpetuate social and 
economic inequality.
Conclusion
There is an urgent need for public 
consultation, education and awareness 
about the secondary use of health data 
and the possible commercialisation of 
health data in New Zealand. It would be 
unethical for a decision to be made on the 
commercialisation (‘sale’) of public health 
data in the absence of transparent debate. 
It should be noted that there have already 
been some instances of the sale of health 
data in New Zealand.
It is beyond the scope of this article to 
explore the vast ethics literature. However, 
central to the debate is the understanding 
that when individual autonomy and 
rights to privacy and informed consent 
become the focus of ethical attention, 
key understandings of ‘value’, ‘ownership’ 
and ‘social inequality’ can be overlooked. 
Conversely, when attention is focused on 
what is good for the majority (the public 
good), minority concerns (including 
the impact on specific individuals) can 
be left unaddressed, and thus pervasive 
social inequalities can be inadvertently 
perpetuated. We need to move beyond 
utilitarian and rights-based models 
towards considering distributive justice 
frameworks and ethics-of-care models 
when addressing public health and the 
uses of public health data, particularly if 
commercialisation is being considered.
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Staff and associates of the 
Institute for Governance 
and Policy Studies and the 
School of Government 
were saddened to hear of 
the death of Don Gray on 
15 September 2015. Don 
had been a member of the 
editorial board of Policy 
Quarterly since May 2012.
Don was a graduate of Victoria 
University of Wellington. He worked 
briefly at State Insurance, then from 
1984 found his niche in policy advice 
roles in the Department of Social 
Welfare and its successor organisations 
(Ministry of Social Policy, Ministry 
of Social Development), including 
as Deputy Chief Executive, Social 
Development Policy and Knowledge, at 
MSD. 
His career included two 
secondments to the OECD in Paris, a 
secondment to the Beehive, chairing 
the Social Policy Committee Senior 
Officials Group and advising the chair 
of the Committee for a number of 
years. From April 2010 to February 
2011, Don managed the secretariat for 
the Welfare Working Group, based in 
the Institute for Governance and Policy 
Studies. He then returned to MSD as 
Chief Policy Advisor, before being 
appointed Deputy Director-General 
Policy at the Ministry of Health from 
January 2012.
Major policy projects Don worked 
on included the Social Report, the 
reform of disability policies in the 
early 1990s, the 2011 Kia Tütahi 
Relationship Accord between the 
Government and the community and 
voluntary sector and every major 
review since the mid-1980s of the New 
Zealand social security system and 
its interfaces with tax, employment, 
housing and disability policies. During 
the 2000s, he steered the development 
of Working for Families, a $1.5 billion 
package and the single most significant 
development in New Zealand’s welfare 
provision for a generation.
Don was a public servant of robust 
intellect and deep integrity, who 
encouraged his colleagues in the nicest 
possible way to maintain a distinction 
between the use and abuse of evidence 
in policy formation. He had a quick 
wit and wry sense of humour. (When 
I met up with him in April he was 
undergoing medical treatment and 
quipped that of course he was merely 
user-testing public health services.) 
Don was a good man who 
treated everyone with respect and 
demonstrated public service excellence 
in working for a better New Zealand. 
A feature of his career was genuine 
concern for citizen outcomes, and he 
found the changes associated with the 
1991 ‘mother of all budgets’ particularly 
challenging. His death is a great loss to 
the policy community, as to his family 
and friends.
David Bromell
Obituary  
Donald Stephen Gray (22 Dec 1959 – 15 Sep 2015)
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